An 8‐week, open‐label, dose‐finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations — latest news, discussion & facts — IJR
An 8‐week, open‐label, dose‐finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations
scholarly article
An 8‐week, open‐label, dose‐finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations
scientific article published on September 12, 2017
